GUTS

Fractyl Health, Inc. Common Stock NASDAQ Listed Feb 2, 2024

Healthcare ·Biotechnology ·US · fractyl.com

$0.75

Mkt Cap $54.0M

52w Low $0.38 14.0% of range 52w High $3.03

50d MA $0.52 200d MA $1.17

P/E (TTM) -0.4x

EV/EBITDA -1.5x

P/B 5.6x

Debt/Equity 6.5x

ROE -1490.3%

P/FCF -1.8x

RSI (14) —

ATR (14) —

Beta 1.19

50d MA $0.52

200d MA $1.17

Avg Volume 3.5M

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.

CIK (SEC)

1572616

Phone

781-902-8800

17 Hartwell Avenue · Lexington, MA 02421 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 24, 2026	AMC	-0.19	0.15	+178.9%	0.43	+13.8%	+16.2%	-5.4%	-5.2%	-4.8%	+7.2%	—
Nov 12, 2025	AMC	-0.34	-0.35	-2.9%	1.13	+11.5%	-0.9%	+12.5%	+13.5%	-2.1%	-5.0%	—
Aug 12, 2025	AMC	-0.37	-0.53	-43.2%	0.98	+0.1%	+2.7%	-3.2%	+4.4%	-1.0%	-1.9%	—
May 13, 2025	AMC	-0.49	-0.49	+0.0%	1.77	-4.0%	-13.0%	+7.1%	+2.4%	+25.4%	-0.9%	—
Mar 3, 2025	AMC	-0.44	-0.52	-18.2%	1.56	-5.1%	-3.8%	+6.0%	-1.3%	-10.2%	+1.4%	—
Nov 12, 2024	AMC	-0.50	-0.48	+4.0%	2.43	+0.8%	-2.5%	-11.8%	-5.7%	+4.6%	+6.3%	—
Aug 14, 2024	AMC	-0.46	-0.36	+21.7%	2.23	+3.1%	+5.4%	+1.7%	+13.8%	+5.9%	+4.2%	—
May 13, 2024	AMC	-0.30	-0.75	-150.0%	6.10	+2.8%	+8.5%	+8.0%	-6.4%	+5.5%	-1.3%	—
Apr 1, 2024	AMC	-0.65	-8.02	-1133.8%	7.45	-5.0%	-9.5%	+9.1%	+1.8%	-1.6%	+3.8%	—
Sep 30, 2023	AMC	—	-0.33	—	—	—	—	—	—	—	—	—
Jun 30, 2023	AMC	—	-0.63	—	—	—	—	—	—	—	—	—
Mar 31, 2023	AMC	—	-0.25	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.58	$0.59	+1.5%	+6.7%	+5.3%	+0.5%	-8.3%	+5.9%
Mar 26	Canaccord Genuity	Maintains	Buy → Buy	—	$0.50	$0.48	-4.2%	-5.4%	-5.2%	-4.8%	+7.2%	+1.5%
Jan 30	Morgan Stanley	Downgrade	Overweight → Equal Weight	—	$0.58	$0.57	-3.1%	-21.4%	+2.7%	-5.3%	-4.9%	-6.0%
Dec 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.56	$1.55	-0.6%	+17.9%	+4.3%	+3.1%	+3.0%	+9.3%
Nov 21	Canaccord Genuity	Maintains	Buy → Buy	—	$1.29	$1.32	+2.3%	+8.5%	+4.3%	+0.0%	+1.4%	+6.1%
Sep 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.01	$1.20	+18.8%	+32.7%	+11.9%	+6.0%	-7.5%	+6.8%
Aug 14	Canaccord Genuity	Maintains	Buy → Buy	—	$1.01	$0.98	-2.9%	-3.2%	+4.4%	-1.0%	-1.9%	-1.1%
Feb 3	Morgan Stanley	Maintains	Overweight → Overweight	—	$1.84	$1.78	-3.3%	-7.6%	-9.4%	+6.5%	-1.8%	-6.2%

Data updated apr 25, 2026 12:43pm · Source: massive.com